Ibrutinib plus rituximab in symptomatic Japanese patients with Waldenström's macroglobulinemia
Naohiro Sekiguchi, MD, PhD, National Hospital Organization Disaster Medical Center, Tachikawa, Japan, discusses a study investigating ibrutinib plus rituximab in symptomatic patients with Waldenström's macroglobulinemia in Japan. Positive findings from this study supported the approval of this combination in Japan. This interview took place at the 12th International Workshop on Waldenström's Macroglobulinemia (IWWM-12) in Prague, Czech Republic.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Watch video Ibrutinib plus rituximab in symptomatic Japanese patients with Waldenström's macroglobulinemia online without registration, duration hours minute second in high quality. This video was added by user VJHemOnc – Video Journal of Hematology & HemOnc 24 October 2024, don't forget to share it with your friends and acquaintances, it has been viewed on our site 70 once and liked it 0 people.